Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date

Francesco Facchinetti, Luc Friboulet INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, FranceCorrespondence: Francesco FacchinettiINSERM U981, Gustave Roussy Cancer Campus, 114 Rue Edouard, Villejuif 94800, FranceTel + 33 14 211 5662Email Francesco.Facchinetti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Facchinetti F, Friboulet L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Lung cancer ROS1 Tyrosine kinase inhibitors Entrectinib. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/86eac883de4548c38cf524c882715cd7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:86eac883de4548c38cf524c882715cd7
record_format	dspace
spelling	oai:doaj.org-article:86eac883de4548c38cf524c882715cd72021-12-02T08:33:57ZProfile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date1179-2728https://doaj.org/article/86eac883de4548c38cf524c882715cd72019-09-01T00:00:00Zhttps://www.dovepress.com/profile-of-entrectinib-and-its-potential-in-the-treatment-of-ros1-posi-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Francesco Facchinetti, Luc Friboulet INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, FranceCorrespondence: Francesco FacchinettiINSERM U981, Gustave Roussy Cancer Campus, 114 Rue Edouard, Villejuif 94800, FranceTel + 33 14 211 5662Email Francesco.Facchinetti@gustaveroussy.frAbstract: ROS1 inhibition provides impressive survival benefits in ROS1-rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer. In addition, several TKI have been tested with preliminary proofs of success in this oncogene-driven disease, either in the post-crizotinib setting or as first-line targeted agents. Here we present the evidence concerning entrectinib, an ALK/ROS1/NTRK inhibitor developed across different tumor types harboring rearrangements in these genes, in the context of ROS1-driven NSCLC. Of interest, in August 2019 entrectinib was granted by FDA accelerated approval for the treatment of ROS1-rearranged NSCLC, as well as of NTRK-driven solid tumors.Keywords: lung cancer, ROS1, tyrosine kinase inhibitors, entrectinibFacchinetti FFriboulet LDove Medical PressarticleLung cancerROS1Tyrosine kinase inhibitorsEntrectinib.Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 10, Pp 87-94 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Lung cancer ROS1 Tyrosine kinase inhibitors Entrectinib. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Lung cancer ROS1 Tyrosine kinase inhibitors Entrectinib. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Facchinetti F Friboulet L Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
description	Francesco Facchinetti, Luc Friboulet INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, FranceCorrespondence: Francesco FacchinettiINSERM U981, Gustave Roussy Cancer Campus, 114 Rue Edouard, Villejuif 94800, FranceTel + 33 14 211 5662Email Francesco.Facchinetti@gustaveroussy.frAbstract: ROS1 inhibition provides impressive survival benefits in ROS1-rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer. In addition, several TKI have been tested with preliminary proofs of success in this oncogene-driven disease, either in the post-crizotinib setting or as first-line targeted agents. Here we present the evidence concerning entrectinib, an ALK/ROS1/NTRK inhibitor developed across different tumor types harboring rearrangements in these genes, in the context of ROS1-driven NSCLC. Of interest, in August 2019 entrectinib was granted by FDA accelerated approval for the treatment of ROS1-rearranged NSCLC, as well as of NTRK-driven solid tumors.Keywords: lung cancer, ROS1, tyrosine kinase inhibitors, entrectinib
format	article
author	Facchinetti F Friboulet L
author_facet	Facchinetti F Friboulet L
author_sort	Facchinetti F
title	Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
title_short	Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
title_full	Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
title_fullStr	Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
title_full_unstemmed	Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
title_sort	profile of entrectinib and its potential in the treatment of ros1-positive nsclc: evidence to date
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/86eac883de4548c38cf524c882715cd7
work_keys_str_mv	AT facchinettif profileofentrectinibanditspotentialinthetreatmentofros1positivensclcevidencetodate AT fribouletl profileofentrectinibanditspotentialinthetreatmentofros1positivensclcevidencetodate
_version_	1718398496922402816

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date

Ejemplares similares